

The 16th International Conference on Progress in Vaccination Against Cancer (PIVAC-16)

12 - 14 September 2016 at Winchester, UK

Organizer: European Association for Cancer Research

Title of conference: The 16th International Conference on Progress in Vaccination Against Cancer (PIVAC-16)

Date & Location: 12 - 14 September 2016 at Winchester, UK

Short description: Progress in Vaccination Against Cancer (PIVAC) aims to bring together translational and clinical oncologists and immunologists dealing with active vaccination against cancer for three days of presentations on the most recent advances in the field. The meeting provides an up-to-date overview of many aspects of tumour immunology. Thanks to its friendly atmosphere and the limited number (max 100) of participants, PIVAC cultivates lively and fruitful discussions, promotes interactions between participants, speakers and companies attending the conference and encourages the emergence of new partnerships.

Who should attend? PIVAC is dedicated to scientists working on active immunization against cancer, both in prevention and therapy, at the pre-clinical and/or clinical level. PIVAC is also an ideal environment to stimulate the interest of students and young researchers who approach this field of research.

Conference website: <http://www.eacr.org/pivac16/index.php>

Deadlines:

Abstract Submission Deadline: 30 June 2016

Registration Deadline: 31 July 2016

Contact Person: Laura Strachan <L.Strachan@nottingham.ac.uk>

Speakers

David Adams (UK), Federica Cavallo (Italy), Vincenzo Cerundolo (UK), Mark Cobbold (USA), Kate Cuschieri (UK), Martijn den Brok (Netherlands), Martin Glennie (UK), Kevin Harrington (UK), Sarah Howie (UK), Emma King (UK), Victor Klimyuk (Germany), Lena M. Kranz (Germany), Jane Lebkowski (USA), Dario Neri (Switzerland), Klaus Okkenhaug (UK), Christian Ottenmeier (UK), Sergio Quezada (UK), Thomas J. Sayers (USA), Stephen Schoenberger (USA), Benoît van den Eynde (UK), Sjoerd van der Burg (Netherlands), Pandurangan Vijayanand (USA), Stephan Wagner (Austria)

Keywords: Nucleic acid vaccines; Plant derived vaccines; Viral targeting of cancer; Phosphopeptide targeting; Immunological adjuvancy through PI3K inhibition and chemotherapy; Immunostimulatory antibodies; Role of B-cells in solid cancers